Morgan Stanley
CLGN icon

Morgan Stanley’s CollPlant Biotechnologies CLGN Stock Holding History

Morgan Stanley’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 8395
2026
Q1 		– Hold
0
– – – 8276
2025
Q4 		– Sell
-241
Closed -$4.93K – 8166
2025
Q3 		$6.47K Buy
+241
New +$5.75K ﹤0.01% 7022
2025
Q2 		– Hold
0
– – – 8064
2025
Q1 		– Hold
0
– – – 8039
2024
Q4 		– Hold
0
– – – 7923
2024
Q3 		– Hold
0
– – – 7874
2024
Q2 		– Hold
0
– – – 7790
2024
Q1 		– Hold
0
– – – 7773
2023
Q4 		– Sell
-12
Closed -$657 – 7748
2023
Q3 		$674 Hold
12
– – ﹤0.01% 7275
2023
Q2 		$987 Sell
12
-5
-29% -$364 ﹤0.01% 7295
2023
Q1 		$1.2K Hold
17
– – ﹤0.01% 7326
2022
Q4 		$1.43K Hold
17
– – ﹤0.01% 7419
2022
Q3 		$1K Buy
17
+12
+240% +$974 ﹤0.01% 7550
2022
Q2 		$0 Sell
5
-20
-80% -$1.84K ﹤0.01% 7825
2022
Q1 		$3K Sell
25
-47
-65% -$5.17K ﹤0.01% 7676
2021
Q4 		$12K Buy
72
+67
+1,340% +$12K ﹤0.01% 7407
2021
Q3 		$1K Sell
5
-10
-67% -$1.8K ﹤0.01% 7758
2021
Q2 		$3K Buy
+15
New +$2.4K ﹤0.01% 7480

Other funds holding CLGN

PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $243M AUM 8.27% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Morgan Stanley's CLGN Position: Q2 2026 in Review

Morgan Stanley held its CollPlant Biotechnologies (CLGN) position steady in Q2 2026 at 0 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #8395.

Morgan Stanley first reported a position in CLGN in Q2 2021 and has held it in 11 quarters since. The position peaked at $12K in Q4 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

  • Morgan Stanley held 0 shares of CollPlant Biotechnologies worth $1 as of Q2 2026.
  • Morgan Stanley left its CollPlant Biotechnologies share count unchanged in Q2 2026.
  • CollPlant Biotechnologies made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8395 holding.
  • Morgan Stanley first reported a position in CollPlant Biotechnologies in Q2 2021 and has held it in 11 quarters since.
  • Morgan Stanley's CollPlant Biotechnologies position peaked at $12K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.